Mubritinib

Mubritinib

Mubritinib (also known as TAK-165) is a protein kinase inhibitor specifically designed to target and inhibit the HER2/neu receptor, a protein that plays a significant role in the progression of certain types of cancer, including breast cancer and gastric cancer.

History

Mubritinib was developed by Takeda Pharmaceutical Company, a Japanese multinational pharmaceutical and biopharmaceutical company. The drug was initially developed as a potential treatment for HER2-positive breast cancer, a subtype of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2).

Mechanism of Action

Mubritinib works by inhibiting the activity of the HER2/neu receptor. This receptor is overexpressed in certain types of cancer cells, leading to uncontrolled cell growth and proliferation. By blocking the activity of this receptor, mubritinib can help to slow down or stop the growth of cancer cells.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of mubritinib in patients with HER2-positive breast cancer. However, the results of these trials have been mixed, and further research is needed to determine the optimal use of this drug in the treatment of cancer.

Side Effects

Like all chemotherapy drugs, mubritinib can cause side effects. These may include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include heart problems, liver problems, and severe allergic reactions.

Future Research

Future research on mubritinib will likely focus on identifying the patient populations that are most likely to benefit from this treatment, as well as determining the optimal dosing and administration strategies.